Traws Pharma, Inc.

DB:0T20 株式レポート

時価総額:€13.8m

Traws Pharma 将来の成長

Future 基準チェック /06

Traws Pharma is forecast to grow revenue at 1% per annum. EPS is expected to grow by 76.3% per annum.

主要情報

n/a

収益成長率

76.3%

EPS成長率

Pharmaceuticals 収益成長18.0%
収益成長率1.0%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日09 Oct 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

DB:0T20 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20250N/AN/AN/A1
12/31/20240N/AN/AN/A1
6/30/20240-137-23-23N/A
3/31/20240-18-18-18N/A
12/31/20230-19-18-18N/A
9/30/20230-20-17-17N/A
6/30/20230-21-17-17N/A
3/31/20230-21-17-17N/A
12/31/20220-19-16-16N/A
9/30/20220-17-17-17N/A
6/30/20220-15-17-17N/A
3/31/20220-16-17-17N/A
12/31/20210-16-19-19N/A
9/30/20210-19-21-21N/A
6/30/20210-22-22-22N/A
3/31/20210-25-23-23N/A
12/31/20200-25-23-23N/A
9/30/20200-24-23-23N/A
6/30/20200-23-21-21N/A
3/31/20202-19-21-21N/A
12/31/20192-22-21-21N/A
9/30/20192-21-21-21N/A
6/30/20192-22-24-24N/A
3/31/20191-23-24-24N/A
12/31/20181-21-23-23N/A
9/30/20181-21-22-22N/A
6/30/20181-23-22-22N/A
3/31/20181-21N/A-23N/A
12/31/20171-24N/A-24N/A
9/30/20171-23N/A-24N/A
6/30/20172-18N/A-19N/A
3/31/20174-21N/A-17N/A
12/31/20166-20N/A-16N/A
9/30/201615-11N/A-16N/A
6/30/201615-15N/A-22N/A
3/31/201613-19N/A-26N/A
12/31/201511-24N/A-31N/A
9/30/20152-41N/A-40N/A
6/30/20150-50N/A-46N/A
3/31/20150-57N/A-51N/A
12/31/20141-64N/A-58N/A
9/30/20143-65N/A-61N/A
6/30/20144-71N/A-62N/A
3/31/20144-68N/A-64N/A
12/31/20135-65N/A-61N/A

アナリストによる今後の成長予測

収入対貯蓄率: Insufficient data to determine if 0T20's forecast earnings growth is above the savings rate (0.8%).

収益対市場: Insufficient data to determine if 0T20's earnings are forecast to grow faster than the German market

高成長収益: Insufficient data to determine if 0T20's earnings are expected to grow significantly over the next 3 years.

収益対市場: 0T20's revenue (1% per year) is forecast to grow slower than the German market (5.5% per year).

高い収益成長: 0T20's revenue (1% per year) is forecast to grow slower than 20% per year.


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: Insufficient data to determine if 0T20's Return on Equity is forecast to be high in 3 years time


成長企業の発掘